Astellas Pharma announced its results for the second quarter of the fiscal year ending March 2027 on 4 November 2026. Operating profit for the April to September period rose 58.8% year on year to ¥316.5 billion, and the share price rose sharply the following day after the full-year outlook was revised upward.
Astellas Pharma announced its second-quarter results on 4 November 2026, reporting higher revenue for the April to September period than in the same period of the previous year. Higher sales of key strategic products in particular contributed to earnings growth, with operating profit rising to ¥316.5 billion. Profit before tax also increased significantly, while net income continued to trend higher.
According to the earnings summary, operating profit for the April to September period increased 58.8% year on year, while revenue rose 23.4% to ¥1.27 trillion. The company cited the growing penetration of key strategic products and the expansion of new indications as the main factors.
In market reaction, the share price rose 6.88% from the previous day to as high as ¥2,672.5 on 5 November, and trading volume also increased. The market reportedly saw more active price movements and trading immediately after the results announcement.
Improved first-half performance also contributed to an improvement in the equity ratio and higher EPS, supporting an upward revision to the full-year outlook. However, attention is considered necessary regarding future risk factors, including currency fluctuations, cost management and regional trends.